MUSTANG BIO, INC. (MBIO): restructuring charge — Mustang Bio cuts workforce by 81% amid CFIUS uncertainty and facility sale to uBriGene

MUSTANG BIO, INC.

Board approved ~81% workforce reduction to reduce costs and preserve capital due to fundraising environment and CFIUS review of facility sale.
Workforce reduction expected substantially complete in Q2 2024; expects ~$0.2M in one-time termination cash expenditures.
Company continues to evaluate all strategic and other alternatives related to the business.
Sale of leasehold interest and assets to uBriGene (Chinese CDMO) pending CFIUS review; terms not disclosed.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

MUSTANG BIO, INC. announced a restructuring with charges of approximately $0.2 million (approximately 81% of its employee base).

Type: restructuring
Charge: approximately $0.2 million
Headcount: approximately 81% of its employee base

Exact text from the filing

to be substantially completed in the second quarter of 2024. As a result of these actions, Mustang expects to incur personnel-related restructuring charges of approximately $0.2 million in connection with one-time employee termination cash expenditures, which are expected to be incurred in the second quarter of 2024. Mustang may also incur other charges or cash

View on SEC.gov

20 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-005022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.